TWI337865B - Aripiprazole oral solution - Google Patents
Aripiprazole oral solution Download PDFInfo
- Publication number
- TWI337865B TWI337865B TW091108139A TW91108139A TWI337865B TW I337865 B TWI337865 B TW I337865B TW 091108139 A TW091108139 A TW 091108139A TW 91108139 A TW91108139 A TW 91108139A TW I337865 B TWI337865 B TW I337865B
- Authority
- TW
- Taiwan
- Prior art keywords
- present
- pharmaceutical solution
- specific example
- water
- pharmaceutical
- Prior art date
Links
- 229940072100 aripiprazole oral solution Drugs 0.000 title 1
- 239000003186 pharmaceutical solution Substances 0.000 claims description 83
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 60
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 31
- 239000002904 solvent Substances 0.000 claims description 25
- 235000011187 glycerol Nutrition 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 235000014655 lactic acid Nutrition 0.000 claims description 13
- 239000004310 lactic acid Substances 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- 230000002079 cooperative effect Effects 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 7
- 239000005715 Fructose Substances 0.000 claims description 7
- 229930091371 Fructose Natural products 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- 235000013355 food flavoring agent Nutrition 0.000 claims description 7
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 7
- 239000000600 sorbitol Substances 0.000 claims description 7
- 235000010356 sorbitol Nutrition 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 235000019441 ethanol Nutrition 0.000 claims description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- 229960004372 aripiprazole Drugs 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 description 17
- 239000003765 sweetening agent Substances 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229920001223 polyethylene glycol Polymers 0.000 description 13
- 239000002202 Polyethylene glycol Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000003755 preservative agent Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 229960000448 lactic acid Drugs 0.000 description 11
- 238000013019 agitation Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 239000013043 chemical agent Substances 0.000 description 7
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical group C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 238000007639 printing Methods 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000002738 chelating agent Substances 0.000 description 5
- 235000021096 natural sweeteners Nutrition 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229930182843 D-Lactic acid Natural products 0.000 description 3
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical group C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229940022769 d- lactic acid Drugs 0.000 description 3
- 239000008180 pharmaceutical surfactant Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WFXLRLQSHRNHCE-UHFFFAOYSA-N 2-(4-amino-n-ethylanilino)ethanol Chemical compound OCCN(CC)C1=CC=C(N)C=C1 WFXLRLQSHRNHCE-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- KVZLHPXEUGJPAH-QNDGGIRCSA-N rac-lactic acid Chemical compound C[C@@H](O)C(O)=O.C[C@H](O)C(O)=O KVZLHPXEUGJPAH-QNDGGIRCSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical group C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
1337865 經濟部智丛財產局資工消费合作社印製 A7 B7_五、發明説明（1) 發明領域： 本發明係關於適於口服投藥之艾瑞皮哌唑 (A r i p i p r a ζ ο 1 e)藥學溶液。 發明背慑= 精神分裂爲一種常見類型的精神病，其特徵爲會妄想 、有幻覺及極端退縮遠離他人。精神分裂的發作一般係在 年齡1 6到25歲間且在全世界中每1 00人就有1名患者。 其比起阿茲海默氏症、多重硬化、胰島素相關的糖尿病及 肌營養不良症更爲普遍。早期診斷及治療可以明顯地改善 康復結果。再者，提早作治療性介入可以避免昂貴的醫療 照護。 艾瑞皮哌唑，即7-{4[4-(2,3-二氯苯基）-1-哌嗪蕋]-丁 氧基}-3,4-二氫鸣諾酮或7-{4[4-(2,3-二氯苯基）-1-哌嗪越 ]-丁氧基}-3,4-二氫-2(1H)-U|諾酮，爲一種治療精神分裂 之非典型治療劑（美國第4,734,41 6號及美國5,006,528號） 。一種適於口服投藥之艾瑞皮哌唑藥學溶液可以符合罹患 精神分裂而難以呑嚥固體口服劑型藥物之患者的需要。配 方艾瑞皮哌唑之口服溶液之挑戰在於需使用適於長期投藥 且適於兒科及老年病患者的溶劑來溶解難溶的藥物，同時 還得緩和該藥物極苦的味道及保持藥物的安定性。 發明目的及槪沭： 所以’本發明之第一項要點係在提供一種適於口服投 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） (請先閱讀背面之注意事項再填寫本頁)1337865 Ministry of Economic Affairs, Zhi Cong Property Bureau, Capital Employment Consortium, Printing A7 B7_5, Invention Description (1) Field of the Invention: The present invention relates to a medicinal solution of Aripiprazil (A ripipra ζ ο 1 e) suitable for oral administration . Inventive Recitation = Schizophrenia is a common type of mental illness characterized by delusions, hallucinations, and extreme withdrawals away from others. The onset of schizophrenia is usually between the ages of 16 and 25 years and there is one patient per 100 people in the world. It is more common than Alzheimer's disease, multiple sclerosis, insulin-related diabetes, and muscular dystrophy. Early diagnosis and treatment can significantly improve recovery outcomes. Furthermore, early interventional interventions can avoid expensive medical care. Aripipiperazole, 7-{4[4-(2,3-dichlorophenyl)-1-piperazinium]-butoxy}-3,4-dihydronorthrone or 7-{ 4[4-(2,3-Dichlorophenyl)-1-piperazine aceto-butoxy}-3,4-dihydro-2(1H)-U|N-one, a treatment for schizophrenia Atypical therapeutic agents (US 4,734,41 6 and US 5,006,528). A pharmaceutical solution of eriripiperazole suitable for oral administration can meet the needs of patients suffering from schizophrenia and having difficulty in swallowing solid oral dosage forms. The challenge of formulating an oral solution of eripiripipazole is to use a solvent suitable for long-term administration and suitable for pediatric and geriatric patients to dissolve the poorly soluble drug, while also easing the bitter taste of the drug and maintaining the stability of the drug. Sex. OBJECT AND OBJECTS OF THE INVENTION: Therefore, the first point of the present invention is to provide a Chinese National Standard (CNS) A4 specification (210X297 mm) for a paper size suitable for oral administration (please read the notes on the back and fill in the form) This page)
*π*π
-4- 1337865 A7 B7 經濟部智慈財產局資工消費合作社印製 五、發明説明（勿 藥之藥學溶液，其含有艾瑞皮哌唑（Aripiprazole)，一種藥 學適用之溶劑系統，一或多種滋味-增進劑/蓋味劑及一或 多種選自乳酸、醋酸、酒石酸及檸檬酸所組成之群組之化 學劑，其中該溶液之pH値爲從2.5到4.5。 本發明第二項要點之第一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該pH値爲2.5到4.0。 本發明第二項要點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該pH値爲2.5到3.8。 本發明第二項要點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該pH値爲3.0到3.6。 本發明第二項耍點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該pH値爲3.1到3.3 » 本發明第三項要點之第一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該化學劑爲乳酸。 本發明第三項要點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該化學劑爲醋酸。 本發明第三項要點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該化學劑爲酒石酸。 本發明第三項要點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該化學劑爲檸檬酸。 本發明第三項要點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該化學劑爲D_乳酸。 本發明第三項要點之再一具體例係在提供一種本發明 第一·項要點之藥學溶液，其中該化學劑爲L _乳酸。 I紙張尺度適用中國i家料（⑽“德 乂297公$ (請先閲讀背面之注意事項再填寫本頁)-4- 1337865 A7 B7 Ministry of Economic Affairs, Zhici Property Bureau, Shigong, Consumer Cooperatives, Printing 5, Invention Description (Pharmaceutical solution for medicine, which contains Aripiprazole, a pharmaceutically acceptable solvent system, one or more a taste-promoting agent/sealing agent and one or more chemical agents selected from the group consisting of lactic acid, acetic acid, tartaric acid, and citric acid, wherein the pH of the solution is from 2.5 to 4.5. The second aspect of the present invention The first specific embodiment is a pharmaceutical solution according to the first aspect of the present invention, wherein the pH 値 is from 2.5 to 4.0. A further specific example of the second aspect of the present invention is to provide a pharmacy according to the first aspect of the present invention. a solution wherein the pH 値 is from 2.5 to 3.8. A further embodiment of the second aspect of the present invention provides a pharmaceutical solution according to the first aspect of the present invention, wherein the pH 値 is from 3.0 to 3.6. Still another specific example is to provide a pharmaceutical solution according to the first aspect of the present invention, wherein the pH 値 is 3.1 to 3.3. The first specific example of the third aspect of the present invention provides a first item of the present invention. Pharmacy solution The liquid wherein the chemical agent is lactic acid. A further embodiment of the third aspect of the present invention provides a pharmaceutical solution according to the first aspect of the present invention, wherein the chemical agent is acetic acid. Further one of the third gist of the present invention A specific example is a pharmaceutical solution according to the first aspect of the present invention, wherein the chemical agent is tartaric acid. A further specific example of the third aspect of the present invention provides a pharmaceutical solution according to the first aspect of the present invention, wherein The chemical agent is citric acid. A further specific example of the third aspect of the present invention provides a pharmaceutical solution according to the first aspect of the present invention, wherein the chemical agent is D_lactic acid. Further specific to the third aspect of the present invention For example, the pharmaceutical solution of the first aspect of the present invention is provided, wherein the chemical agent is L-lactic acid. I paper size is applicable to Chinese i-materials ((10) "Deyi 297 public$ (please read the back note first) Fill in this page)
、1T, 1T
-5- 1337865 經濟部智慧財產局8工消費合作社印紫 A7 ------- -B7_1、發明説明（含 # # 0$ m Ξ項斐點之再一具體例係在提供—種本發明 第〜項要點之藥寧溶液，其中該乳酸爲L-乳酸D-乳酸之 混合物。 本發明第三項要點之再一具體例係在提供—種本發明 〜一要點之藥攀溶液，其中該乳酸爲L-乳酸及D-乳酸 之外消旋混合物。 Μ胃ΙΏ頃要點之第一具體例係在提供一種本發明 〜1頁要點之樂擧溶液，其中該乳酸存在的濃度爲0.7毫 克/毫升到丨S毫兑/電升。 Φ Μ Μ胃0 1胃要點之再一具體例係在提供一種本發明 第〜項要點之藥擧溶液，其中該乳酸存在的濃度爲35毫 克/毫升到1 4 · 5笔克/毫升。 #胃m ΕΗ頃要點之再一具體例係在提供一種本發明 項要點之_學溶液，其中該乳酸存在的濃度爲5.4毫 克/毫升到9毫克/毫升。 本：發明第五項要點之第一具體例係在提供一種本發明 胃—項要點之藥擧溶液，其中該艾瑞皮哌唑存在的濃度爲 〇·〇5毫克/毫升到6毫克/毫升。 本發明第五項要點之再一具體例係在提供一種本發明 第—項要點之藥學溶液，其中該艾瑞皮哌唑存在的濃度爲 0.1毫克/毫升到3毫克/毫升。 本發明第五項要點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該艾瑞皮哌唑存在的濃度爲 0.25毫克/毫升到2毫克/毫升。 本紙張尺度適用中國國家標準（CNS ) Α4規格（2ΙΟΧ297公釐） (請先閲讀背面之注意事項再填寫本頁)-5- 1337865 Ministry of Economic Affairs Intellectual Property Bureau 8 Workers Consumption Cooperatives India Purple A7 ------- -B7_1, Invention Description (including # # 0$ m Ξ项斐点 Further specific examples are provided - The drug solution of the first aspect of the invention, wherein the lactic acid is a mixture of L-lactic acid D-lactic acid. A further specific example of the third aspect of the present invention provides a drug solution of the present invention. The lactic acid is a racemic mixture of L-lactic acid and D-lactic acid. The first specific example of the sputum is to provide a solution of the essence of the present invention, wherein the lactic acid is present at a concentration of 0.7 mg. /ml to 丨S milli/electric liter. Φ Μ Μ stomach 0 1 Another specific example of the stomach point is to provide a drug solution of the first item of the present invention, wherein the lactic acid is present at a concentration of 35 mg / ml To 1 4 · 5 pg / ml. Another example of the gut m is to provide a solution of the present invention, wherein the concentration of the lactic acid is 5.4 mg / ml to 9 mg / ml The first specific example of the fifth aspect of the invention is to provide a stomach of the present invention. The drug solution of the main point, wherein the concentration of the ericopiperazole is 〇·〇 5 mg/ml to 6 mg/ml. A further specific example of the fifth aspect of the present invention provides a method of the present invention. The pharmaceutical solution of the present invention, wherein the concentration of the eripiropazole is from 0.1 mg/ml to 3 mg/ml. A further specific example of the fifth aspect of the present invention is to provide a pharmacy according to the first aspect of the present invention. A solution in which the concentration of the erpipirazole is from 0.25 mg/ml to 2 mg/ml. The paper size is applicable to the Chinese National Standard (CNS) Α4 specification (2ΙΟΧ297 mm) (please read the notes on the back and fill in the form) This page)
、1Τ1Τ
-6- 1337865 經濟部智惩財凌局8工消費合作社印3^ --—_______B7_ 五、發明説明（涔 本發明第五項要點之再一具體例係在提供一種本發明 胃〜項要點之藥導i溶液’其中該艾瑞皮哌唑存在的濃度爲 〇·75毫克/毫升到L5毫克/毫升。 本發明第五項要點之再一具體例係在提供一種本發明 胃〜項要Si之藥學溶液，其中該艾瑞皮哌唑存在的濃度爲 1毫克/毫升。 本發明第六項要點之第一具體例係在提供—種本發明 胃〜項要點之藥學溶液，其中該藥學適用的溶劑系統包含 水。 本發明第六項要點之再一具體例係在提供一種本發明 胃—項要點之藥學溶液，其中該藥學適用的溶劑系統包含 水及一或多種介面活性劑。 本發明第六項要點之再一具體例係在提供一種本發明 第—項要點之藥學溶液，其中該藥學適用的溶劑系統包含 水及一或多種助溶劑。 本發明第六項要點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該藥學適用的溶劑系統包含 水’一或多種介面活性劑及一或多種助溶劑。 本發明第六項要點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該藥學適用的溶劑系統包含 水及一或多種可與水溶混之溶劑 本發明第六項要點之再一具體例係在提供一種本發明 第—項要點之藥學溶液，其中該藥學適用的溶劑系統包含 水’一或多種可與水溶混之溶劑及一或多種介面活性劑。 (請先閲讀背面之注意事項再填寫本頁)-6- 1337865 Ministry of Economic Affairs, Zhi Pun, Financial Bureau, 8 Workers' Cooperatives, Printing 3^ ---_______B7_ V. Description of the Invention (A further example of the fifth aspect of the present invention is to provide a stomach of the present invention. The drug guide i solution 'where the concentration of the eripiropazole is 〇·75 mg/ml to L5 mg/ml. A further specific example of the fifth aspect of the present invention is to provide a stomach of the present invention. The pharmaceutical solution, wherein the concentration of the erpipirazole is 1 mg/ml. The first specific example of the sixth aspect of the present invention provides a pharmaceutical solution for the stomach of the present invention, wherein the pharmaceutical is suitable for use. The solvent system comprises water. A further embodiment of the sixth aspect of the invention provides a pharmaceutical solution of the stomach of the invention, wherein the pharmaceutically suitable solvent system comprises water and one or more interfacing agents. A further specific example of the sixth aspect is the provision of a pharmaceutical solution according to the first aspect of the invention, wherein the pharmaceutically acceptable solvent system comprises water and one or more co-solvents. A specific example is a pharmaceutical solution according to the first aspect of the present invention, wherein the pharmaceutically acceptable solvent system comprises water 'one or more surfactants and one or more cosolvents. Yet another specific example of the sixth aspect of the present invention Provided is a pharmaceutical solution according to the first aspect of the present invention, wherein the pharmaceutically acceptable solvent system comprises water and one or more water-miscible solvents. Still another specific example of the sixth aspect of the present invention provides a present invention. The pharmaceutical solution of the first item, wherein the pharmaceutically suitable solvent system comprises water, one or more water-miscible solvents and one or more surfactants. (Please read the back note first and then fill out this page)
••IT••IT
本紙張尺度適用中國國家標準（CNS )A4規格（210X297公釐） 經濟部智慧財凌局肖工消費合作社印製 1337865 A7 ____ B7__ 五、發明説明（今 本發明第六項要點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該藥學適用的溶劑系統包含 水’一或多種可與水溶混之溶劑及一或多種助溶劑。 本發明第六項要點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該藥學適用的溶劑系統包含 水’ 一或多種可與水溶混之溶劑，一或多種介面活性劑及 一或多種助溶劑。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該可與水溶混之 溶劑係選自乙醇、甘油、丙二醇、山梨糖醇、聚乙二醇、 聚乙烯吡咯啶酮（P〇vidone)及苯甲醇所組成之群組。 本發明第六項耍點之再一具體例係在提供一種本發明 胃A項要點其它具體例之藥學溶液，其中該可與水溶混之 溶劑係選自甘油、丙二醇、LMW聚乙二醇及山梨糖醇所 組成之群組。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該可與水溶混之 溶劑係選自甘油、丙二醇及山梨糖醇所組成之群組。 本發明第六項耍點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該介面活性劑及 該藥學可接受之介面活性劑所具之親水性-親脂性平衡値 (HLB)爲1 5或更高。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該介面活性劑及 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） (請先閲讀背面之注意事項再填寫本頁)This paper scale is applicable to China National Standard (CNS) A4 specification (210X297 mm). Ministry of Economic Affairs, Smart Finance Bureau, Xiaogong Consumer Cooperative, Printing 1337865 A7 ____ B7__ V. Invention Description (More specific examples of the sixth point of the present invention) A pharmaceutical solution for providing a first aspect of the present invention, wherein the pharmaceutically acceptable solvent system comprises water, one or more water miscible solvents and one or more cosolvents. Further specific to the sixth aspect of the present invention The invention provides a pharmaceutical solution according to the first aspect of the invention, wherein the pharmaceutically suitable solvent system comprises water, one or more water miscible solvents, one or more interfacing agents and one or more cosolvents. A further specific example of the sixth aspect is to provide a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the water-miscible solvent is selected from the group consisting of ethanol, glycerin, propylene glycol, sorbitol, and polyethylene. A group consisting of alcohol, polyvinylpyrrolidone (P〇vidone) and benzyl alcohol. A further specific example of the sixth aspect of the present invention provides a present invention. Item A is a pharmaceutical solution of another specific example, wherein the water-miscible solvent is selected from the group consisting of glycerin, propylene glycol, LMW polyethylene glycol, and sorbitol. Further specific to the sixth aspect of the present invention The invention provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the water-miscible solvent is selected from the group consisting of glycerin, propylene glycol and sorbitol. Still another specific embodiment provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the surfactant-accepting agent and the pharmaceutically acceptable surfactant have a hydrophilic-lipophilic balance (HLB) of 1 5 or more. Another specific example of the sixth aspect of the present invention provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the surfactant and the paper scale are applicable to the Chinese National Standard (CNS) A4. Specifications (210X297 mm) (Please read the notes on the back and fill out this page)
-8- 1337865 A7 B7 經濟部智慈財產局資工消費合作社印製 五、發明説明（彡 該藥學可接受之介面活性劑係選自脂肪酸酯、聚氧化乙烧 脂肪酸酯（山梨聚糖-Sorbitan)，聚氧化乙烯單烷基醚及 P〇l〇xamers所組成之群組。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該介面活性劑及 該藥學可接受之介面活性劑係選自TWEEN®、BRI]®及 pluronics(Pluracare®)所組成之群組。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該藥學助溶劑係 選自povidon及環糊精。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該丙二醇、甘油 及水存在的比例分別爲0.8-1.2:2.4-3.6:6.4-9.6 w/w。 本發明第六項耍點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該丙二醇、甘油 及水存在的比例分別爲0.9-1.1:2.7-3.3:7.2-88 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該丙二醇、甘油 及水存在的比例分別爲1: 3 : 8 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該甘油、丙二醇 及水存在的比例分別爲0.8-1.2:2.4-3.6:6.4-9.6 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該甘油、丙二醇 (請先閲讀背面之注意事項再填寫本頁)-8- 1337865 A7 B7 Ministry of Economic Affairs Zhici Property Bureau, Shigong, Consumer Cooperatives Printing 5, Invention Description (The pharmaceutically acceptable surfactant is selected from fatty acid esters, polyoxyethylene sulphonate fatty acid esters (sorbitan) -Sorbitan), a group consisting of polyoxyethylene monoalkyl ether and P〇l〇xamers. A further specific example of the sixth aspect of the present invention provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention. Wherein the surfactant and the pharmaceutically acceptable surfactant are selected from the group consisting of TWEEN®, BRI]® and pluronics (Pluracare®). Further specific examples of the sixth aspect of the present invention are provided A pharmaceutical solution according to another specific example of the present invention, wherein the pharmaceutical auxiliary solvent is selected from the group consisting of povidon and cyclodextrin. Further specific examples of the sixth aspect of the present invention provide a sixth aspect of the present invention. a specific example of the pharmaceutical solution, wherein the ratio of the propylene glycol, the glycerin and the water is 0.8-1.2: 2.4-3.6: 6.4-9.6 w/w, respectively. Further specific examples of the sixth aspect of the present invention provide a The sixth point of invention Another specific example of the pharmaceutical solution, wherein the ratio of the propylene glycol, glycerin and water is 0.9-1.1: 2.7-3.3: 7.2-88 w/w, respectively. Further specific examples of the sixth aspect of the present invention provide a The sixth aspect of the invention is the pharmaceutical solution of the other specific examples, wherein the ratio of the propylene glycol, the glycerin, and the water is 1:3:8 w/w, respectively. Still another specific example of the sixth aspect of the present invention provides the present invention. The sixth aspect is the pharmaceutical solution of another specific example, wherein the ratio of the glycerin, the propylene glycol and the water is 0.8-1.2: 2.4-3.6: 6.4-9.6 w/w, respectively. Further specific examples of the sixth aspect of the present invention are Provided is a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the glycerin and propylene glycol (please read the back sheet and read the following page)
*?τ*?τ
本纸張尺度適用中國國家標準（CNS ) Α4規格（210Χ297公釐） -9 - 1337865 經濟部智慈財產局員工消費合作社印製 A7 B7 五、發明説明（7) 及水存在的比例分別爲〇. 9 -1.1:2.7 - 3.3:7.2 - 8.8 w / W。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該甘油、丙二醉 及水存在的比例分別爲1:3 :8 w / w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該聚乙二醇及水 存在的比例分別爲0.8-1.2:3.2-4.8 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該聚乙二醇及水 存在的比例分別爲0.9-1. 1:3.6-4.4 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該聚乙二醇及水 存在的比例分別爲1:4 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該聚乙二醇、丙 二醇及水存在的比例分別爲16-2.4:0.8-1.2:6.4-8.6 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該聚乙二醇、丙 二酉？及水存在的比例分別爲18-2.2:0.9-1.1:7.2-8.8 w/w。 本發明第六項耍點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該聚乙二醇、丙 二醇及水存在的比例分別爲2:1: 8 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該聚乙二醇、甘 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） (請先間讀背面之注意事項再填寫本頁)This paper scale applies to China National Standard (CNS) Α4 specification (210Χ297 mm) -9 - 1337865 Ministry of Economic Affairs Zhici Property Bureau employee consumption cooperative printed A7 B7 V. Invention description (7) and the proportion of water existence are 9 -1.1:2.7 - 3.3:7.2 - 8.8 w / W. Still another specific example of the sixth aspect of the present invention provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the ratio of the glycerin, the propylene glycol, and the water is 1:3:8 w / w, respectively. . Still another specific example of the sixth aspect of the present invention provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the ratio of the polyethylene glycol and water is 0.8-1.2: 3.2-4.8 w/ w. A further specific example of the sixth aspect of the present invention provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the ratio of the polyethylene glycol and water is 0.9-1. 1:3.6-4.4 w/w. Still another specific example of the sixth aspect of the present invention provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the polyethylene glycol and water are present in a ratio of 1:4 w/w, respectively. Still another specific example of the sixth aspect of the present invention provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the ratio of the polyethylene glycol, the propylene glycol and the water is 16-2.4: 0.8-1.2, respectively. : 6.4-8.6 w/w. Still another specific example of the sixth aspect of the present invention provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the polyethylene glycol or propylene glycol? The ratio of water and water is 18-2.2:0.9-1.1:7.2-8.8 w/w. A further specific example of the sixth aspect of the present invention provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the ratio of the polyethylene glycol, the propylene glycol and the water is 2:1:8 w, respectively. /w. A further specific example of the sixth aspect of the present invention provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the polyethylene glycol and the paper size of the paper are applicable to the Chinese National Standard (CNS) A4 specification (210X297). PCT) (Please read the back of the note first and then fill out this page)
-10- 1337865 A 7 B7 五、發明説明（沒 油及水存在的比例分別爲1.6-2.4:0.8-1.2:6.4-8.6 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該聚乙二醇、甘 油及水存在的比例分別爲1.8-2.2:0.9-1.1:7.2-8.8 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該聚乙二醇、甘 油及水存在的比例分別爲2:1:8 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它Μ體例之藥學溶液，其中該甘油及水存在 的比例分別爲 0.8 -1.2: 6.4- 8.6 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該甘油及水存在 的比例分別爲 〇.9-1.1:7.2-8.8 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該甘油及水存在 的比例分別爲1:8 w / w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該聚乙二醇及水 存在的比例分別爲1.6-2.4:6.4-8.6 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該聚乙二醇及水 存在的比例分別爲1. 8 - 2.2 :7.2 - 8.8 w/w。 本發明第六項要點之再一具體例係在提供一種本發明 第六項要點其它具體例之藥學溶液，其中該聚乙二醇及水 本紙張尺度適用中國國家標準（CNS ) Α4規格（210X 297公釐） (請先閲讀背面之注意事項再填寫本頁) ip -='β 經濟部智慧財產局S工消費合作社印製 -11 - 1337865 A7 B7 經濟部智慈財凌局8工消費合作社印製 五、發明説明（g 存在的比例分別爲2:8 w/w。 本發明第七項要點之第一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該滋味-增進劑/蓋味劑含有 〜或多種增甜劑。 本發明第七項耍點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該滋味-增進劑/蓋味劑含有 一或多種矯味劑。 本發明第七項要點之再一具體例係在提供一種本發明 第一項要點之藥學溶液，其中該滋味—增進劑/蓋味劑含有 ~或多種增甜劑及一或多種矯味劑。 本發明第七項要點之再一具體例係在提供一種本發明 第七項要點第一具體例之藥學溶液，其中該增甜劑含有一 或多種天然增甜劑。 本發明第七項要點之再一具體例係在提供一種本發明 第七項要點第一具體例之藥學溶液，其中該增甜劑含有一 或多種半合成增甜劑。 本發明第七項要點之再一具體例係在提供一種本發明 第七項要點第一具體例之藥學溶液，其中該增甜劑含有一 或多種合成增甜劑。 本發明第七項要點之再一具體例係在提供一種本發明 第七項要點第一具體例之藥學溶液，其中該增甜劑含有一 或多種天然增甜劑及一或多種半合成增甜劑。 本發明第七項要點之再一具體例係在提供一種本發明 第七項要點第一具體例之藥學溶液，其中該增甜劑含有一 (請先閱讀背面之注意事項再填寫本頁)-10- 1337865 A 7 B7 V. INSTRUCTIONS (The ratio of oil and water is 1.6-2.4: 0.8-1.2: 6.4-8.6 w/w respectively. Another specific example of the sixth point of the present invention is provided. A pharmaceutical solution according to another specific example of the present invention, wherein the polyethylene glycol, glycerin and water are present in a ratio of 1.8 to 2.2: 0.9 to 1.1: 7.2 to 8.8 w/w, respectively. Still another specific example is to provide a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the polyethylene glycol, glycerin and water are present in a ratio of 2:1:8 w/w, respectively. A further specific example of the present invention provides a pharmaceutical solution according to another embodiment of the present invention, wherein the glycerin and water are present in a ratio of 0.8 to 1.2: 6.4 to 8.6 w/w, respectively. Still another specific example is to provide a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the ratio of the glycerin and water is 〇.9-1.1: 7.2-8.8 w/w, respectively. Still another specific example is to provide a pharmacy according to another specific example of the sixth aspect of the present invention. a solution wherein the glycerin and water are present in a ratio of 1:8 w / w. A further specific example of the sixth aspect of the present invention provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein the poly The ratio of ethylene glycol and water is 1.6-2.4: 6.4-8.6 w/w, respectively. A further specific example of the sixth aspect of the present invention provides a pharmaceutical solution according to another specific example of the sixth aspect of the present invention, wherein The ratio of the polyethylene glycol and the water is 1. 8 - 2.2 : 7.2 - 8.8 w / w. Another specific example of the sixth aspect of the present invention is to provide a specific example of the sixth aspect of the present invention. Pharmaceutical solution, in which the polyethylene glycol and water-based paper scales are applicable to the Chinese National Standard (CNS) Α4 specification (210X 297 mm) (please read the notes on the back and fill out this page) ip -='β Ministry of Economics Property Bureau S Workers Consumption Cooperative Printed -11 - 1337865 A7 B7 Ministry of Economic Affairs Zhici Finance Bureau 8 Workers Consumption Cooperative Printed 5, invention description (g exists in the ratio of 2:8 w/w respectively. The seventh item of the invention The first specific example of the main point is to provide a first invention of the present invention The pharmaceutical solution of the present invention, wherein the taste-enhancing agent/covering agent contains ~ or a plurality of sweeteners. A further specific example of the seventh aspect of the present invention provides a pharmaceutical solution according to the first aspect of the present invention, wherein The taste-enhancing agent/sealing agent contains one or more flavoring agents. Still another specific example of the seventh aspect of the present invention provides a pharmaceutical solution according to the first aspect of the present invention, wherein the taste-enhancing agent/covering taste The agent contains ~ or more sweeteners and one or more flavoring agents. Still another specific example of the seventh aspect of the present invention provides a pharmaceutical solution according to the first specific example of the seventh aspect of the present invention, wherein the sweetener contains one or more natural sweeteners. Still another specific example of the seventh aspect of the present invention provides a pharmaceutical solution according to the first specific example of the seventh aspect of the present invention, wherein the sweetener contains one or more semi-synthetic sweeteners. Still another specific example of the seventh aspect of the present invention provides a pharmaceutical solution according to the first specific example of the seventh aspect of the present invention, wherein the sweetener contains one or more synthetic sweeteners. A further specific example of the seventh aspect of the present invention provides a pharmaceutical solution according to the first embodiment of the seventh aspect of the present invention, wherein the sweetener contains one or more natural sweeteners and one or more semi-synthetic sweetened Agent. Still another specific example of the seventh aspect of the present invention provides a pharmaceutical solution according to the first specific example of the seventh aspect of the present invention, wherein the sweetener contains one (please read the back note first and then fill in the page)
*π*π
本紙張尺度適用中國國家揉準（CNS)A4規格（210χ 297公釐） -12- 1337865 A7 B7This paper scale applies to China National Standard (CNS) A4 specification (210χ 297 mm) -12- 1337865 A7 B7
i、發明説明（1)D 或多種天然增甜劑及一或多種合成增甜劑。 本發明第七項要點之再一具體例係在提供一種本發明 第七項要點第一貝體例之藥學溶液，其中該增甜劑含有一 或多種半合成增甜劑及一或多種合成增甜劑a 本發明第七項要點之再—具體例係在提供一種本發明 第七項要點第一具體例之藥學溶液，其中該增甜劑含有一 或多種天然增甜劑、一或多種半合成增甜劑及一或多種合 成增甜劑。 本發明第七項要點之再一具體例係在提供一種本發明 第七項要點個別具體例之藥學溶液，其中該天然增甜劑係 選自鹿糖、果糖、右旋糖、麥芽糖、葡萄糖及甘油所組成 之群組。 本發明第七項要點之再一具體例係在提供一種本發明 第七項要點個別具體例之藥學溶液，其中該半合成增甜齊^ 係選自乳糖醇、麥芽糖醇、木糖醇、山梨糖醇及甘露糖醇 所組成之群組。 本發明第七項要點之再一具體例係在提供一種本發明 第七項要點個別具體例之藥學溶液，其中該合成增甜劑係 選自糖精、acesulfame鉀及阿斯巴甜所組成之群組。 本發明第七項要點之再一具體例係在提供一種本發明 第七項要點個別具體例之藥學溶液，其中該矯味劑係選自 樱桃、柑橘、薄荷、草莓、大茴香、桃子、覆盆子及橙霜 所組成之群組。 本發明第八項要點之第一具體例係在提供一種本發明 本紙張尺度適用中國國家標準（CNS ) Λ4規格（210X297公釐） (請先M讀背面之注意事項再填寫本页) % *•11 經濟部智慈財產局員工消費合作社印製 -13- ⑴ 7865i. Description of the Invention (1) D or a plurality of natural sweeteners and one or more synthetic sweeteners. Still another specific example of the seventh aspect of the present invention provides a pharmaceutical solution of the first aspect of the present invention, wherein the sweetener contains one or more semi-synthetic sweeteners and one or more synthetic sweetening agents. A further embodiment of the present invention provides a pharmaceutical solution according to the first embodiment of the seventh aspect of the present invention, wherein the sweetener contains one or more natural sweeteners, one or more semi-synthetic A sweetener and one or more synthetic sweeteners. A further specific example of the seventh aspect of the present invention provides a pharmaceutical solution according to a specific embodiment of the seventh aspect of the present invention, wherein the natural sweetener is selected from the group consisting of deer sugar, fructose, dextrose, maltose, glucose and A group of glycerol. Still another specific example of the seventh aspect of the present invention provides a pharmaceutical solution according to a specific embodiment of the seventh aspect of the present invention, wherein the semi-synthetic sweetening system is selected from the group consisting of lactitol, maltitol, xylitol, and sorbitol A group consisting of sugar alcohols and mannitol. A further specific example of the seventh aspect of the present invention provides a pharmaceutical solution according to a specific embodiment of the seventh aspect of the present invention, wherein the synthetic sweetener is selected from the group consisting of saccharin, acesulfame potassium and aspartame. group. Still another specific example of the seventh aspect of the present invention provides a pharmaceutical solution according to a specific embodiment of the seventh aspect of the present invention, wherein the flavoring agent is selected from the group consisting of cherry, citrus, mint, strawberry, anise, peach, and raspberry. And a group of orange creams. The first specific example of the eighth aspect of the present invention is to provide a Chinese National Standard (CNS) Λ4 specification (210×297 mm) for the paper scale of the present invention (please read the following on the back of the M). •11 Ministry of Economic Affairs Zhici Property Bureau employee consumption cooperative printing-13- (1) 7865
經濟部智慧財產局負工消費合作社印製 i、發明説明（咖 第一項要點之藥學溶液，其中該溶液進一步含有一或多種 藥學可接受的保存劑。 本發明第八項要點之再一具體例係在提供一種本發明 m八項要點第一具體例之藥學溶液，其中該保存劑含有一 或多種抗菌性保存劑。 本發明第八項耍點之再一具體例係在提供一種本發明 八項要點第一具體例之藥學溶液，其中該保存劑含有一 或多種抗氧化劑。 本發明第八項要點之再一具體例係在提供一種本發明 第八項要點第一具體例之藥學溶液，其中該保存劑含有一 或多種螯合劑。 本發明第八項要點之再一具體例係在提供一種本發明 $八項要點第一具體例之藥學溶液，其中該保存劑含有一 或多種抗菌性保存劑及一或多種抗氧化劑。 本發明第八項要點之再一具體例係在提供一種本發明 $八項要點第一具體例之藥學溶液，其中該保存劑含有一 或多種抗菌性保存劑及一或多種螯合劑。 本發明第八項要點之再一具體例係在提供一種本發明 胃八項要點第一具體例之藥學溶液，其中該保存劑含有一. 或多種抗氧化劑及一或多種蝥合劑。 本發明第八項要點之再一具體例係在提供一種本發明 第八項要點第一具體例之藥學溶液，其中該保存劑含有— 或多種抗菌性保存劑、一或多種抗氧化劑及一或多種螯合 劑。 本紙張尺度適用中國國家標準（CNS ) A4規格（210X29*7公釐） (請先閱讀背面之注意事項再填寫本頁)The Ministry of Economic Affairs, the Intellectual Property Office, the Consumers' Cooperative, printed i, the invention description (the first point of the pharmacy solution, wherein the solution further contains one or more pharmaceutically acceptable preservatives. Further specific to the eighth aspect of the present invention The present invention provides a pharmaceutical solution according to the first specific example of the present invention, wherein the preservative contains one or more antibacterial preservatives. Further specific examples of the eighth aspect of the present invention provide a present invention. Eight points are the pharmaceutical solutions of the first specific example, wherein the preservative contains one or more antioxidants. A further specific example of the eighth aspect of the present invention provides a pharmaceutical solution according to the first specific example of the eighth aspect of the present invention. Wherein the preservative comprises one or more chelating agents. A further embodiment of the eighth aspect of the present invention provides a pharmaceutical solution according to the first embodiment of the present invention, wherein the preservative contains one or more antibacterial agents. A sexual preservative and one or more antioxidants. A further specific example of the eighth aspect of the present invention provides a medicine of the first specific example of the eight essential points of the present invention. a solution, wherein the preservative contains one or more antibacterial preservatives and one or more chelating agents. Still another specific example of the eighth aspect of the present invention provides a pharmaceutical solution of the first specific example of the eight points of the stomach of the present invention, Wherein the preservative comprises one or more antioxidants and one or more chelating agents. A further specific embodiment of the eighth aspect of the present invention provides a pharmaceutical solution according to the first specific example of the eighth aspect of the present invention, wherein the preserving The agent contains - or a plurality of antibacterial preservatives, one or more antioxidants and one or more chelating agents. The paper size applies to the Chinese National Standard (CNS) A4 specification (210X29*7 mm) (please read the precautions on the back) Fill in this page)
•-'1·•-'1·
-14- 1337865 A7 _B7____ 五、發明説明（l)2 本發明第八項要點之再一具體例係在提供一種本發明 第八項要點個別具體例之藥學溶液，其中該抗菌性保存劑 係選自對羥基苯甲酸甲酯、對羥基苯甲酸乙酯、對羥基苯 甲酸丙酯、對羥基苯甲酸丁酯 '苯甲酸、苯甲酸鈉、苯甲 醇、山梨酸及山梨酸鈉所組成的群組。 本發明第八項要點之再一具體例係在提供一種本發明 第八項要點個別具體例之藥學溶液，其中該抗氧化劑係選 自偏亞硫酸氫鈉、亞硫酸氫鈉、五倍子酸丙酯、抗壞血酸 鈉及抗壞血酸所組成之群組。 本發明第八项要點之再一具體例係在提供一種本發明 第八項要點個別具體例之藥學溶液，其中該螯合劑係選自 EDTA二鈉、酒石酸、蘋果酸及檸檬酸所組成之群組。 本發明第九項要點係在提供一種本發明第一項要點第 —具體例之藥學溶液，其中該溶液基本上不含有懸浮粒子 〇 本發明其它具體例可提供一種藥學溶液，其係將在此 所述之兩個或多個具體例適當組合而成。 本發明其它具體例可根據如下所提供之說明而更爲明 顯。 發明詳細說明： 除非另有說明，在此使用時”乳酸”包括D-乳酸、L-乳 酸及/或其混合物。 於下文提供本發明適當製劑之非限制性實施例。 本纸張尺度適用中國國家標準（CNS ) A4规格（210X297公釐） (請先閱讀背面之注意事項再填寫本頁)-14- 1337865 A7 _B7____ V. INSTRUCTION DESCRIPTION (1) 2 Another specific example of the eighth aspect of the present invention is to provide a pharmaceutical solution according to an individual specific example of the eighth aspect of the present invention, wherein the antibacterial preservative is selected A group consisting of methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzoic acid, sodium benzoate, benzyl alcohol, sorbic acid, and sodium sorbate. Still another specific example of the eighth aspect of the present invention provides a pharmaceutical solution according to an individual specific example of the eighth aspect of the present invention, wherein the antioxidant is selected from the group consisting of sodium metabisulfite, sodium hydrogen sulfite, and propyl gallate. a group consisting of sodium ascorbate and ascorbic acid. A further specific example of the eighth aspect of the present invention provides a pharmaceutical solution according to an individual specific example of the eighth aspect of the present invention, wherein the chelating agent is selected from the group consisting of EDTA disodium, tartaric acid, malic acid and citric acid. group. The ninth aspect of the present invention provides a pharmaceutical solution according to the first aspect of the present invention, wherein the solution contains substantially no suspended particles. The other specific examples of the present invention provide a pharmaceutical solution, which will be herein. The two or more specific examples are appropriately combined. Other embodiments of the invention will be apparent from the description provided below. DETAILED DESCRIPTION OF THE INVENTION: "Lactic acid" as used herein, unless otherwise indicated, includes D-lactic acid, L-lactic acid, and/or mixtures thereof. Non-limiting examples of suitable formulations of the invention are provided below. This paper size applies to the Chinese National Standard (CNS) A4 specification (210X297 mm) (please read the notes on the back and fill out this page)
經濟部智慧財產局S工消費合作社印製 -15- 1337865 A7 B7 五、發明説明（也 實施例1:Printed by the Ministry of Economic Affairs, Intellectual Property Bureau, S-Consumer Cooperatives -15- 1337865 A7 B7 V. Description of the invention (also Example 1:
表1 實施例1 口服液 成份 m g / m L 艾瑞皮哌唑 1 · 0 P E G - 4 0 0 12 5 D L —乳酸 8 ♦ 4 7 氫氧化鈉* 0-45(1) 苯甲酸 1 · 5 蔗糖 3 6 0 果糖 3 5 0 天然橙霜矯味劑 3 ♦ 0 純水 Q S (請先閱讀背面之注意事項再填寫本頁)Table 1 Example 1 Oral solution mg / m L Irispiperazole 1 · 0 PEG - 4 0 0 12 5 DL - lactic acid 8 ♦ 4 7 Sodium hydroxide * 0-45 (1) Benzoic acid 1 · 5 sucrose 3 6 0 Fructose 3 5 0 Natural Orange Cream Flavor 3 ♦ 0 Pure Water QS (Please read the notes on the back and fill out this page)
-a (1)該氫氧化鈉的確實份量可能與所顯示者有所不同 以將批次溶液的pH値調整到3.1至3.2間。-a (1) The exact portion of the sodium hydroxide may differ from the one shown to adjust the pH of the batch solution to between 3.1 and 3.2.
經濟部智慈財產局8工消費合作社印製 -16- 1337865 A7 B7 五 '發明説明（1)4 步驟3之批次物之pH値調整到3.1至3.2間。 4. 在連續地溫和攪拌下，將步驟3的批次物加熱到 45-551： 〇然後在將溫度維持在45-55°C下加入苯甲酸。藉 目視觀察確定所有粉末均已溶解。 5. 將步驟4的批次物之溫度降到40-50°C，加入蔗糖 及果糖且加以混和。藉目視觀察確定所有粉末均已溶解。 6. 在連續地溫和攪拌下，將步驟5之溶液冷卻到25-3 0°C。 7. 在連續地溫和攪拌下，將矯味劑加到步驟6之溶液 且予以混合。 8. 在連續地溫和搅拌下，將足量的水加到步驟7的批 次物中來調整最終批次物的體積且予以混合。 9. 使步驟8的溶液通過不銹鋼篩過濾。 10. 將步驟9之溶液儲存在槽中。 實施例2 (請先閲讀背面之注意事項再填寫本页)Ministry of Economic Affairs Zhici Property Bureau 8 Workers Consumption Cooperative Printed -16- 1337865 A7 B7 V'Inventive Note (1)4 The pH of the batch of step 3 is adjusted to 3.1 to 3.2. 4. Heat the batch from Step 3 to 45-551 with continuous gentle agitation: then add benzoic acid while maintaining the temperature at 45-55 °C. All powders were dissolved by visual observation. 5. Reduce the temperature of the batch from step 4 to 40-50 ° C, add sucrose and fructose and mix. All powders were dissolved by visual observation. 6. Cool the solution from step 5 to 25-3 0 ° C with gentle agitation. 7. Add the flavor to the solution from step 6 and mix with gentle agitation. 8. Add a sufficient amount of water to the batch of step 7 with constant gentle agitation to adjust the volume of the final batch and mix. 9. Filter the solution from step 8 through a stainless steel screen. 10. Store the solution from step 9 in the tank. Example 2 (Please read the notes on the back and fill out this page)
-1¾ 經濟部智.¾財產局員工消費合作社印製 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -17- 1337865 五、發明説明（1)5 表2 實施例2 口服液 成份 m g / m L . 艾瑞皮哌唑（100%純度） 1 · 0 自由，USP/EP/BP 15 0-0 DL-乳酸，USP/EP 8 · 4 7 氫氧化鈉，NF/EP/BP 〇 . 4 5 ( 1 ) 丙二醇，USP/EP 5 〇 * 〇 對羥基苯甲酸甲酯，NF/BP/EP 1 · 8 _ _ 對羥基苯甲酸丙酯，NF/BP/EP 0 · 2 蔗糖，NF/BP/EP 4 0 0-0 果糖，USP/EP/BP 2 0 0*0 天然橙霜矯味劑WONF(2) 3 · 〇 _ 純水USP/EP α . s . _ ... (1)該氫氧化鈉的確實份量可能與所顯示者有所不同 (請先閲讀背面之注意事項再填寫本頁)-13⁄4 Ministry of Economic Affairs Zhizhi. 3⁄4 Property Bureau Staff Consumer Cooperatives Printed Paper Size Applicable to China National Standard (CNS) A4 Specification (210X297 mm) -17- 1337865 V. Invention Description (1) 5 Table 2 Example 2 Oral Liquid Ingredient mg / m L . Eric Piperazole (100% Purity) 1 · 0 Free, USP/EP/BP 15 0-0 DL-Lactic Acid, USP/EP 8 · 4 7 Sodium Hydroxide, NF/EP/BP 4. 4 5 ( 1 ) Propylene glycol, USP/EP 5 〇* 甲酯 methyl paraben, NF/BP/EP 1 · 8 _ _ propyl paraben, NF/BP/EP 0 · 2 sucrose, NF/BP/EP 4 0 0-0 Fructose, USP/EP/BP 2 0 0*0 Natural Orange Cream Flavoring Agent WONF(2) 3 · 〇_ Pure Water USP/EP α . s . _ ... (1 The exact amount of sodium hydroxide may differ from what is shown (please read the notes on the back and fill out this page)
、-», -»
以將批次溶液的pH値調整到3.1至3.2間。 (2)WONF意指”以及其它天然矯味劑”。 經濟部智慧財產局員工消費合作社印製 1. 將甘油及一部份（80-90%)純水加入該批次容器中。 在連續地溫和攪拌下，將DL-乳酸及一部份丙二醇加到該 批次容器中且繼續攪拌直到溶解爲止。 2. 在一容器中，將對羥基苯甲酸甲酯及對羥基苯甲酸 丙酯分散在一份丙二醇中且予以混合。 3. 在連續地溫和攪拌下，將艾瑞皮哌唑加入步驟1的 批次容器中且予以混合。藉目視觀察確定所有粉末均已溶 本纸張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） -18- 1337865 A7 B7 五、發明説明（诟 解。 4. 在連續地溫和攪拌下，加入氫氧化鈉2.5N溶液將 步驟3之批次物之pH値調整到3.1至3.2間。 5. 在連續地溫和攪拌下，將步驟4的批次物加熱到 45-55°C。然後將步驟2之對羥基苯甲酸酯及丙二醇混合 物加到該批次容器中且將溫度維持在45-55°C下予以混合 °藉目視觀察確定所有粉末均已溶解。 6. 將步驟5的批次物之溫度降到40-5CTC，加入蔗糖 及果糖且加以混和。藉目視觀察確定所有粉末均已溶解。 7. 在連績地溫和攒拌下，將步驟6之溶液冷卻到25-3(TC。 8. 在連續地溫和攪拌下，將矯味劑加到步驟7之溶液 且予以混合。 9. 在連續地溫和攪拌下，將足量的水加到步驟8的批 次物中來調整最終批次物的體積且予以混合。 10. 使步驟9的溶液通過不銹鋼篩過濾。 (請先閲讀背面之注意事項再填寫本頁)The pH of the batch solution was adjusted to between 3.1 and 3.2. (2) WONF means "and other natural flavoring agents". Printing by the Intellectual Property Office of the Ministry of Economic Affairs, the Consumer Cooperatives 1. Add glycerin and a portion (80-90%) of pure water to the batch container. DL-lactic acid and a portion of propylene glycol were added to the batch vessel under constant gentle agitation and stirring was continued until dissolved. 2. Disperse methylparaben and propylparaben in a portion of propylene glycol in a single vessel and mix. 3. Add ereipipipazole to the batch container of step 1 and mix with gentle agitation. Visually observe that all powders have been dissolved. The paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X 297 mm) -18- 1337865 A7 B7 V. Description of the invention (诟解. 4. Under continuous mild agitation The pH of the batch of step 3 was adjusted to between 3.1 and 3.2 by adding a 2.5 N solution of sodium hydroxide. 5. The batch of step 4 was heated to 45-55 ° C under continuous gentle agitation. Add the mixture of the paraben and propylene glycol of step 2 to the batch container and mix the temperature at 45-55 ° C. Visually observe that all the powders have dissolved. 6. Step 5 The temperature of the batch was lowered to 40-5 CTC, and sucrose and fructose were added and mixed. All the powders were dissolved by visual observation. 7. Cool the solution of step 6 to 25-3 under gentle mixing. (TC. 8. Add the flavoring agent to the solution of step 7 and mix them under constant gentle agitation. 9. Adjust the amount of water to the batch of step 8 to adjust with continuous gentle agitation. The volume of the final batch is mixed and mixed. 10. Pass the solution of step 9 Stainless steel screen filter. (Please read the notes and then fill in the back of this page)
經濟部智M-財產局K工消費合作社印製 本紙張尺度適用中國國家標準（CNS )A4規格（2丨0X297公釐） -19-Ministry of Economic Affairs, M-Property Bureau, K-Minute Consumer Cooperative Printed This paper scale applies to China National Standard (CNS) A4 specification (2丨0X297 mm) -19-
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28671801P | 2001-04-25 | 2001-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI337865B true TWI337865B (en) | 2011-03-01 |
Family
ID=23099862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW091108139A TWI337865B (en) | 2001-04-25 | 2002-04-19 | Aripiprazole oral solution |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US6977257B2 (en) |
| EP (2) | EP1381367B1 (en) |
| JP (1) | JP4401077B2 (en) |
| KR (1) | KR100909329B1 (en) |
| CN (1) | CN1512884B (en) |
| AR (1) | AR033168A1 (en) |
| AT (1) | ATE537831T1 (en) |
| AU (1) | AU2002254722B2 (en) |
| BG (1) | BG66177B1 (en) |
| BR (1) | BR0208986A (en) |
| CA (1) | CA2445276C (en) |
| CY (1) | CY1112606T1 (en) |
| CZ (1) | CZ306181B6 (en) |
| DK (1) | DK1381367T3 (en) |
| EE (1) | EE05581B1 (en) |
| ES (1) | ES2377855T3 (en) |
| GE (1) | GEP20053602B (en) |
| HK (2) | HK1058316A1 (en) |
| HR (1) | HRP20030870B1 (en) |
| HU (1) | HU230456B1 (en) |
| IL (2) | IL158202A0 (en) |
| IS (1) | IS2863B (en) |
| MX (1) | MXPA03009728A (en) |
| MY (1) | MY129350A (en) |
| NO (1) | NO324606B1 (en) |
| NZ (1) | NZ528550A (en) |
| PE (1) | PE20021086A1 (en) |
| PL (1) | PL206882B1 (en) |
| PT (1) | PT1381367E (en) |
| RS (1) | RS52082B (en) |
| RU (1) | RU2295960C2 (en) |
| SK (1) | SK287948B6 (en) |
| TW (1) | TWI337865B (en) |
| UA (1) | UA76144C2 (en) |
| UY (1) | UY27273A1 (en) |
| WO (1) | WO2002085366A1 (en) |
| ZA (1) | ZA200307797B (en) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770478B2 (en) * | 2000-02-10 | 2004-08-03 | The Regents Of The University Of California | Erythrocytic cells and method for preserving cells |
| ATE428423T1 (en) * | 2002-08-20 | 2009-05-15 | Bristol Myers Squibb Co | ARIPIPRAZOLE COMPLEX FORMULATION AND METHODS |
| EP1680144B1 (en) * | 2003-10-08 | 2011-10-05 | Mallinckrodt LLC | Methylphenidate solution and associated methods of administration and production |
| DK1675573T4 (en) * | 2003-10-23 | 2012-08-06 | Otsuka Pharma Co Ltd | Controlled release sterile injectable aripiprazole formulation and method |
| US20080234291A1 (en) * | 2004-01-21 | 2008-09-25 | Marc Karel Jozef Francois | Mitratapide Oral Solution |
| US20070148100A1 (en) | 2005-09-15 | 2007-06-28 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
| EP1808164B2 (en) * | 2006-01-05 | 2018-07-04 | Teva Pharmaceutical Industries Ltd | Wet granulation method for preparing pharmaceutical compositions of aripiprazole |
| US20070154545A1 (en) * | 2006-01-05 | 2007-07-05 | Julia Hrakovsky | Dry formulations of aripiprazole |
| JP4892264B2 (en) * | 2006-03-30 | 2012-03-07 | 高田製薬株式会社 | Risperidone aqueous solution |
| ATE523602T1 (en) | 2006-06-12 | 2011-09-15 | Hadasit Med Res Service | RGS2 GENOTYPES ASSOCIATED WITH EXTRAPYRAMIDAL SYMPTOMS INDUCED BY ANTIPSYCHOTICS |
| GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| TWI410255B (en) * | 2007-07-31 | 2013-10-01 | Otsuka Pharma Co Ltd | Methods for producing aripiprazole suspension and freeze-dried formulation |
| WO2009042166A1 (en) * | 2007-09-25 | 2009-04-02 | Panacos Pharmaceuticals, Inc. | Liquid bevirimat dosage forms for oral administration |
| GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| CN102753563A (en) | 2008-12-23 | 2012-10-24 | 吉利德制药有限责任公司 | Nucleoside analogs |
| WO2010075554A1 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Synthesis of purine nucleosides |
| PA8855601A1 (en) | 2008-12-23 | 2010-07-27 | NUCLEOSID FORFORMIDATES | |
| TWI598358B (en) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
| WO2010146872A1 (en) * | 2009-06-19 | 2010-12-23 | 株式会社メドレックス | Composition for external application comprising aripiprazole and organic acid as active ingredients |
| TR201000948A1 (en) | 2010-02-09 | 2011-08-22 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Aripiprazole formulations. |
| JP6058528B2 (en) | 2010-03-31 | 2017-01-11 | ギリアド ファーマセット エルエルシー | Nucleoside phosphoramidate |
| PL3290428T3 (en) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
| PL2609923T4 (en) | 2010-03-31 | 2017-11-30 | Gilead Pharmasset Llc | Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate |
| JP6069215B2 (en) | 2010-11-30 | 2017-02-01 | ギリアド ファーマセット エルエルシー | Compound |
| EP2685979B1 (en) | 2011-03-18 | 2016-08-24 | Alkermes Pharma Ireland Limited | Injectable pharmaceutical compositions comprising a water-insoluble anti-psychotic, sorbitan laurate and polysorbate 20 |
| JO3410B1 (en) * | 2011-06-07 | 2019-10-20 | Otsuka Pharma Co Ltd | Freeze-dried aripiprazole formulation |
| CN102846616B (en) * | 2011-06-27 | 2015-05-06 | 上海中西制药有限公司 | Aripiprazole preparation and preparation method thereof |
| CN102846543B (en) * | 2011-06-27 | 2014-11-19 | 上海中西制药有限公司 | Aripiprazole pharmaceutic preparation and preparation method thereof |
| JO3190B1 (en) * | 2011-10-19 | 2018-03-08 | Otsuka Pharma Co Ltd | Solution for oral administration |
| NZ630643A (en) | 2012-03-19 | 2017-08-25 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising fatty acid esters |
| AU2013235523B9 (en) | 2012-03-19 | 2018-01-04 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
| CA2867137C (en) | 2012-03-19 | 2020-12-08 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol |
| JOP20200109A1 (en) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | Injectable preparation |
| JP5341282B1 (en) * | 2012-06-29 | 2013-11-13 | 丸石製薬株式会社 | Aripiprazole oral pharmaceutical formulation |
| US20150174247A1 (en) | 2012-06-29 | 2015-06-25 | Maruishi Pharmaceutical Co., Ltd. | Oral pharmaceutical preparation of aripiprazole |
| KR101571670B1 (en) | 2012-08-08 | 2015-11-25 | 주식회사 씨엠지제약 | Formulation for orodispersible film comprising aripirazole |
| US9193685B2 (en) | 2012-09-19 | 2015-11-24 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| MY179191A (en) * | 2012-09-26 | 2020-10-30 | Pfizer | Apixaban liquid formulations |
| US8568747B1 (en) | 2012-10-05 | 2013-10-29 | Silvergate Pharmaceuticals, Inc. | Enalapril compositions |
| US20140107130A1 (en) * | 2012-10-11 | 2014-04-17 | Antrim Pharmaceuticals, LLC | Oral Solution Formulations of Aripiprazole |
| WO2014060324A1 (en) | 2012-10-16 | 2014-04-24 | Sanovel Ilac Sanayi Ve Ticaret A.S | Aripiprazole formulations |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| JP6203682B2 (en) * | 2013-07-10 | 2017-09-27 | 共和薬品工業株式会社 | Aripiprazole-containing aqueous solution |
| CN103393594A (en) * | 2013-08-22 | 2013-11-20 | 万特制药(海南)有限公司 | Novel aripiprazole preparation composition |
| BR112016021535A8 (en) | 2014-03-20 | 2021-07-20 | Alkermes Pharma Ireland Ltd | kit comprising aripiprazole formulations having increased injection rates useful for the treatment of a central nervous system disorder and use |
| WO2016189504A1 (en) * | 2015-05-28 | 2016-12-01 | Leiutis Pharmaceuticals Pvt Ltd | Non-lyophilized compositions of aripiprazole and methods of preparation thereof |
| JP6039849B1 (en) * | 2015-06-12 | 2016-12-07 | 高田製薬株式会社 | Aripiprazole-containing internal preparation |
| WO2017025930A1 (en) * | 2015-08-12 | 2017-02-16 | Ftf Pharma Private Limited | Oral solution of aripiprazole |
| US9463183B1 (en) | 2015-10-30 | 2016-10-11 | Silvergate Pharmaceuticals, Inc. | Lisinopril formulations |
| US9669008B1 (en) | 2016-03-18 | 2017-06-06 | Silvergate Pharmaceuticals, Inc. | Enalapril formulations |
| CN108434146A (en) * | 2017-02-16 | 2018-08-24 | 天津国际生物医药联合研究院 | A kind of solution and its preparation method and application of HIV-1 integrase inhibitors |
| CN109498556A (en) * | 2017-09-15 | 2019-03-22 | 万特制药(海南)有限公司 | Aripiprazole oral solution and preparation method thereof |
| EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN112666267B (en) * | 2019-10-15 | 2023-09-26 | 上海上药中西制药有限公司 | Method for detecting related substances of aripiprazole drug substance |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU843739A3 (en) † | 1978-02-17 | 1981-06-30 | Карл Томэ Гмбх (Фирма) | Method of preparing carbostyryl or oxyindole derivatives |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| PH17194A (en) * | 1980-03-06 | 1984-06-19 | Otsuka Pharma Co Ltd | Novel carbostyril derivatives,and pharmaceutical composition containing the same |
| JPS5959663A (en) † | 1982-09-29 | 1984-04-05 | Otsuka Pharmaceut Co Ltd | Clathrate compound of carbostyryl derivative and cyclodextrin |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| JP3265680B2 (en) * | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | Oral pharmaceutical composition |
| US5457099A (en) † | 1992-07-02 | 1995-10-10 | Sawai Pharmaceutical Co., Ltd. | Carbostyril derivatives and antiallergic agent |
| TW254855B (en) | 1993-07-28 | 1995-08-21 | Otsuka Pharma Co Ltd | |
| BR9811458A (en) * | 1997-03-31 | 2000-09-19 | Johnson & Johnson Consumer | "solvent system for improved penetration of pharmaceutical compounds" |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| AU6023999A (en) * | 1998-09-03 | 2000-03-27 | Alcide Corporation | Freeze-resistant topical germicides and methods related thereto |
| US20020076437A1 (en) * | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
-
2002
- 2002-03-28 MY MYPI20021124A patent/MY129350A/en unknown
- 2002-04-15 AR ARP020101366A patent/AR033168A1/en unknown
- 2002-04-19 TW TW091108139A patent/TWI337865B/en not_active IP Right Cessation
- 2002-04-24 BR BR0208986-6A patent/BR0208986A/en active Search and Examination
- 2002-04-24 AU AU2002254722A patent/AU2002254722B2/en not_active Expired
- 2002-04-24 CZ CZ2003-2821A patent/CZ306181B6/en not_active IP Right Cessation
- 2002-04-24 CA CA002445276A patent/CA2445276C/en not_active Expired - Fee Related
- 2002-04-24 KR KR1020037013943A patent/KR100909329B1/en active IP Right Grant
- 2002-04-24 PL PL364666A patent/PL206882B1/en unknown
- 2002-04-24 UA UA20031110599A patent/UA76144C2/en unknown
- 2002-04-24 EP EP02723964A patent/EP1381367B1/en not_active Expired - Lifetime
- 2002-04-24 WO PCT/US2002/013048 patent/WO2002085366A1/en active IP Right Grant
- 2002-04-24 JP JP2002582939A patent/JP4401077B2/en not_active Expired - Lifetime
- 2002-04-24 EE EEP200300523A patent/EE05581B1/en not_active IP Right Cessation
- 2002-04-24 DK DK02723964.9T patent/DK1381367T3/en active
- 2002-04-24 ES ES02723964T patent/ES2377855T3/en not_active Expired - Lifetime
- 2002-04-24 AT AT02723964T patent/ATE537831T1/en active
- 2002-04-24 IL IL15820202A patent/IL158202A0/en active IP Right Grant
- 2002-04-24 MX MXPA03009728A patent/MXPA03009728A/en active IP Right Grant
- 2002-04-24 HU HU0303946A patent/HU230456B1/en not_active IP Right Cessation
- 2002-04-24 RU RU2003132426/15A patent/RU2295960C2/en not_active IP Right Cessation
- 2002-04-24 SK SK1264-2003A patent/SK287948B6/en not_active IP Right Cessation
- 2002-04-24 RS YU84703A patent/RS52082B/en unknown
- 2002-04-24 EP EP11190103.9A patent/EP2436384B2/en not_active Expired - Lifetime
- 2002-04-24 CN CN028112148A patent/CN1512884B/en not_active Ceased
- 2002-04-24 GE GE5332A patent/GEP20053602B/en unknown
- 2002-04-24 US US10/131,304 patent/US6977257B2/en not_active Expired - Lifetime
- 2002-04-24 NZ NZ528550A patent/NZ528550A/en not_active IP Right Cessation
- 2002-04-24 UY UY27273A patent/UY27273A1/en not_active Application Discontinuation
- 2002-04-24 PT PT02723964T patent/PT1381367E/en unknown
- 2002-04-25 PE PE2002000346A patent/PE20021086A1/en not_active Application Discontinuation
-
2003
- 2003-10-01 IL IL158202A patent/IL158202A/en not_active IP Right Cessation
- 2003-10-01 BG BG108216A patent/BG66177B1/en unknown
- 2003-10-06 ZA ZA200307797A patent/ZA200307797B/en unknown
- 2003-10-14 IS IS6994A patent/IS2863B/en unknown
- 2003-10-21 NO NO20034705A patent/NO324606B1/en not_active IP Right Cessation
- 2003-10-24 HR HR20030870A patent/HRP20030870B1/en not_active IP Right Cessation
-
2004
- 2004-02-19 HK HK04101190.2A patent/HK1058316A1/en not_active IP Right Cessation
-
2012
- 2012-03-14 CY CY20121100273T patent/CY1112606T1/en unknown
- 2012-09-28 HK HK12109608.1A patent/HK1168792A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI337865B (en) | Aripiprazole oral solution | |
| AU2002254722A1 (en) | Aripiprazole oral solution | |
| JP4549006B2 (en) | Gel ointment | |
| JP5052558B2 (en) | Gel ointment | |
| US8507452B2 (en) | Hesperidin-containing composition | |
| US20150306111A1 (en) | Pharmaceutical composition comprising desloratadine and prednisolone and their use | |
| JP5211677B2 (en) | Oral solution | |
| WO2014149939A1 (en) | Dye free liquid therapeutic solution | |
| TR201514760A1 (en) | NEW ORAL SOLUTION FORMULATION WITH RUPATADINE | |
| JP2000247883A (en) | Liquid agent for internal use containing dihydropyridine- based compound | |
| EP2968573A1 (en) | Dye free liquid therapeutic solution | |
| WO2022247609A1 (en) | Tizanidine liquid preparation and use thereof | |
| TR201510144A2 (en) | NEW ORAL SOLUTION FORMULATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |